New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: Possible consequences for therapeutic drug monitoring in solid organ transplantation

Therapeutic Drug Monitoring

Volumn 31, Issue 4, 2009, Pages 416-435

  Jonge, Hylke De ^a   Naesens, Maarten ^a   Kuypers, Dirk R J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cyclosporine; Mycophenolic acid; Pharmacokinetics; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DRUG METABOLITE; HYPERICUM PERFORATUM EXTRACT; METAL ION; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENOBARBITAL; RESIN; RIFAMPICIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ANEMIA; AREA UNDER THE CURVE; BACTERIAL INFECTION; BLOOD TOXICITY; CARDIAC GRAFT REJECTION; CELL LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DISORDERS OF CARBOHYDRATE METABOLISM; DNA POLYMORPHISM; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG RESEARCH; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENTERIC COATED TABLET; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT REJECTION; LEUKOPENIA; LIVER GRAFT REJECTION; LOW DRUG DOSE; LYMPHOCYTE; MONOTHERAPY; NEOPLASM; NEPHROTOXICITY; NEUROTOXICITY; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; PHARMACOGENETICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED DRUG RELEASE; TOXICITY TESTING;

CALCINEURIN; DRUG MONITORING; ENZYME INHIBITORS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 68449084545     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181aa36cd     Document Type: Review

References (247)

1. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2:374-384.
2. van Gelder TMP, Meur YLMP, Shaw LMP, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28:145-154.
3. Jeong H, Kaplan B. Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol. 2007;2:184-191.
4. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation. 2008;85:1675-1685.
5. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13-58.
6. Stenton SB, Partovi N, Ensom MH. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet. 2005;44:769-786.
7. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83-95.
8. Yano I. Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors. Drug Metab Pharmacokinet. 2008;23:150-157.
9. Hartmann B, Schmid G, Graeb C, et al. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int. 2005;68:2593-2598.
10. Leogrande D, Teutonico A, Ranieri E, et al. Monitoring biological action of rapamycin in renal transplantation. Am J Kidney Dis. 2007;50:314-325.
11. Vethe NT, Bremer S, Rootwelt H, et al. Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. Ther Drug Monit. 2008;30:647-655.
12. Kuypers DRJ, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids. Clin Pharmacokinet. 2004;43:741-762.
13. van Hest RM, Mathot RA, Vulto AG, et al. Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of view. Ther Drug Monit. 2006;28:31-34.
14. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet. 1993;24:472-495.
15. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43:623-653.
16. Kuypers DRJ, Vanrenterghem YC. Tailoring immunosuppressive therapy. Nephrol Dial Transplant. 2002;17:2051-2054.
17. Johnston A, Holt DW. Immunosuppressant drugs-the role of therapeutic drug monitoring. Br J Clin Pharmacol. 2001;52(Suppl 1): 61S-73S.
18. Kelly P, Kahan BD. Review: metabolism of immunosuppressant drugs. Curr Drug Metab. 2002;3:275-287.
19. Meier-Kriesche HU, Li S, Gruessner RWG, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006;6:1111-1131.
20. Chapman JR, Valantine H, Albanell J, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc. 2007;39:2937-2950.
21. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc. 2004;36:378S-391S.
22. Balbontin FG, Kiberd B, Squires J, et al. Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. Transplant Proc. 2003;35:2445-2448.
23. Scholten EM, Cremers SCLM, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67:2440-2447.
24. Mardigyan V, Giannetti N, Cecere R, et al. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus. J Heart Lung Transplant. 2005;24:1614-1618.
25. Keown P, Landsberg D, Halloran P, A randomized, et al. prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Transplantation. 1996;62:1744-1752.
26. Cantarovich M, Barkun JS, Tchervenkov JI, et al. Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation. 1998;66:1621-1627.
27. Cantarovich M, Besner JG, Barkun JS, et al. Two-hour cyclosporine level determination is the appropriate tool to monitor neoral therapy. Clin Transplant. 1998;12:243-249.
28. Mahalati K, Kahan BD. Pharmacological surrogates of allograft outcome. Ann Transplant. 2000;5:14-23.
29. Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation. 2007;83:1525-1535.
30. Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002;300:1036-1045.
31. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm. 2004;277:3-9.
32. Moller A, Iwasaki K, Kawamura A, et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos. 1999;27:633-636.
33. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002;41:813-851.
34. Lampen A, Christians U, Gonschior AK, et al. Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J Pharmacol. 1996;117:1730-1734.
35. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54:1271-1294.
36. Ma X, Idle JR, Gonzalez FJ. The pregnane X receptor: from bench to bedside. Expert Opin Drug Metab Toxicol. 2008;4:895-908.
37. Zhang B, Xie W, Krasowski MD. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics. 2008;9:1695-1709.
38. Kohle C, Bock KW. Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem Pharmacol. 2009;77:689-699.
39. Lim YP, Huang JD. Interplay of pregnane X receptor with other nuclear receptors on gene regulation. Drug Metab Pharmacokinet. 2008;23:14-21.
40. Curtis JJ. Hypertension following kidney transplantation. Am J Kidney Dis. 1994;23:471-475.
41. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation. 1997;63:331-338.
42. Nankivell BJ, Borrows RJ, Fung CLS, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326-2333.
43. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet. 2002;359:741-746.
44. Sperschneider H. A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation. Transplant Proc. 2001;33:1279-1281.
45. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am J Transplant. 2007;7:560-570.
46. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562-2575.
47. Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol. 2008;3(Suppl 2):S101-S116.
48. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Cni sparing with mycophenolate mofetil in de novo renal transplantation: 3-year results from the Symphony study. Transplantation. 2008;86:218-219.
49. Ekberg H, Bernasconi C, Nöldeke J, et al. Cyclosporine, tacrolimus and sirolimus retained their distinct toxicity profiles despite low doses in the Symphony study. Am J Transplant. 2007;7:160.
50. Liang SL, Breaud A, Dunn W, et al. Comparison of the CEDIA and MEIA assays for measurement of tacrolimus in organ transplant recipients. Clin Chim Acta. 2008;396:1-6.
51. Amann SB, Parker TSP, Levine DMP. Evaluation of 2 immunoassays for monitoring low blood levels of tacrolimus. Ther Drug Monit. 2009;31:273-276.
52. Boer K, Deufel T, Schmidt D, et al. Application of the EMIT 2000 Tacrolimus assay on the Abbott Architect c8000 high volume clinical chemistry analyzer. Clin Biochem. 2006;39:1041-1043.
53. Boer K, Brehmer-Streck S, Deufel T, et al. Automated monitoring of C2 and C0 blood levels of mycophenolic acid and cyclosporine on the Abbott Architect c8000. Clin Biochem. 2007;40:1163-1167.
54. Griffey MA, Hock KG, Kilgore DC, et al. Performance of a no-pretreatment tacrolimus assay on the Dade Behring Dimension RxL clinical chemistry analyzer. Clin Chim Acta. 2007;384:48-51.
55. Ansermot N, Fathi M, Veuthey JL, et al. Simultaneous quantification of cyclosporine, tacrolimus, sirolimus and everolimus in whole blood by liquid chromatography-electrospray mass spectrometry. Clin Biochem. 2008;41:728-735.
56. Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc. 2005;37:867-870.
57. Alloway R, Steinberg S, Khalil K, et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation. 2007;83:1648-1651.
58. Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a oncedaily modified release tacrolimus-based regimen. Transplant Proc. 2005;37:1211-1213.
59. Florman S, Alloway R, Kalayoglu M, et al. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation. 2007;83:1639-1642.
60. Heffron TG, Pescovitz MD, Florman S, et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant. 2007;7:1609-1615.
61. Silva HT Jr, Yang HC, Abouljoud M, et al. One-year results with extendedrelease tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant. 2007;7:595-608.
62. Undre NA. Use of a once daily modified release tacrolimus regimen in de novo kidney transplant recipients. Am J Transplant. 2005;5:190.
63. Undre N, Wlodarczyk Z, Ostrowski M, et al. Pharmacokinetics of tacrolimus for a once daily prolonged release formulation (Advagraf) versus twice-daily (Prograf) in de novo kidney transplant recipients in a phase III multicentre study. Transplantation. 2008;86:184-185.
64. Undre NA. Use of a once daily modified release tacrolimus regimen in de novo liver transplant recipients. Am J Transplant. 2005;5:374.
65. Masri MA, Barbari A, Stephan A, et al. Measurement of lymphocyte cyclosporine levels in transplant patients. Transplant Proc. 1998;30:3561-3562.
66. Barbari A, Stephan A, Masri M, et al. Cyclosporine lymphocyte level and lymphocyte count: new guidelines for tailoring immunosuppressive therapy. Transplant Proc. 2003;35:2742-2744.
67. Barbari AG, Masri MA, Stephan AG, et al. Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: a prospective study. Exp Clin Transplant. 2006;4:400-405.
68. Falck P, Asberg A, Guldseth H, et al. Declining intracellular T-lymphocyte concentration of cyclosporine A precedes acute rejection in kidney transplant recipients. Transplantation. 2008;85:179-184.
69. Zahir H, McCaughan G, Gleeson M, et al. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol. 2004;57:298-309.
70. Capron AM, Musuamba FP, Latinne DM, et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in peripheral blood mononuclear cells. Ther Drug Monit. 2009;31:178-186.
71. Sandborn WJ, Lawson GM, Krom RA, et al. Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection. Hepatology. 1992;15:1086-1091.
72. Sandborn WJ, Lawson GM, Cody TJ, et al. Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. Hepatology. 1995;21:70-76.
73. Capron A, Lerut J, Verbaandert C, et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection. Ther Drug Monit. 2007;29:340-348.
74. Christians U, Strom T, Zhang YL, et al. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2006;28:39-44.
75. Crettol S, Venetz JP, Fontana M, et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics. 2008;18:307-315.
76. Elens L, Capron A, Kerckhove VV, et al. 1199>A and 2677>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomics. 2007;17:873-883.
77. Christians U, Sewing KF. Cyclosporin metabolism in transplant patients. Pharmacol Ther. 1993;57:291-345.
78. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22:328-335.
79. Ozbay A, Karamperis N, Jorgensen KA. A review of the immunosuppressive activity of cyclosporine metabolites: new insights into an old issue. Curr Clin Pharmacol. 2007;2:244-248.
80. Karamperis N, Koefoed-Nielsen P, Bagger Sorensen A, et al. Role of metabolites and calcineurin inhibition on C2 monitoring in renal transplant patients. Nephrol Dial Transplant. 2005;20:618-621.
81. Vollenbroeker B, Koch JH, Fobker M, et al. Determination of cyclosporine and its metabolites in blood via HPLC-MS and correlation to clinically important parameters. Transplant Proc. 2005;37:1741-1744.
82. Karamperis N, Koefoed-Nielsen PB, Brahe P, et al. Correlations between calcineurin phosphatase inhibition and cyclosporine metabolites concentrations in kidney transplant recipients: implications for immunoassays. Basic Clin Pharmacol Toxicol. 2006;98:569-574.
83. Chen YL, Hirabayashi H, Akhtar S, et al. Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;830:330-341.
84. Falck P, Guldseth H, Asberg A, et al. Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852:345-352.
85. Koseki N, Nakashima A, Nagae Y, et al. Simultaneous quantitative determination of cyclosporine A and its three main metabolites (AM1, AM4N and AM9) in human blood by liquid chromatography/mass spectrometry using a rapid sample processing method. Rapid Commun Mass Spectrom. 2006;20:733-740.
86. Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther. 2007;82:711-725.
87. Dai Y, Hebert MF, Isoherranen N, et al. Effect of CYP3A5 polymorphisms on tacrolimus metabolic clearance in vitro. Drug Metab Dispos. 2006;34:836-847.
88. Westley IS, Taylor PJ, Salm P, et al. Cloned enzyme donor immunoassay tacrolimus assay compared with high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in liver and renal transplant recipients. Ther Drug Monit. 2007;29:584-591.
89. Yang Z, Wang S. Recent development in application of high performance liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressants. J Immunol Methods. 2008;336:98-103.
90. de Jonge H, Kuypers DR. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant Rev. 2008;22:6-20.
91. Thervet E, Anglicheau D, Legendre C, et al. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit. 2008;30:143-150.
92. Cattaneo D, Baldelli S, Perico N. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises. Am J Transplant. 2008;8:1374-1383.
93. Mourad M, Wallemacq P, De Meyer M, et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation. 2008;85:S19-S24.
94. Goto M, Masuda S, Kiuchi T, et al. CYP3A51-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics. 2004;14:471-478.
95. Uesugi M, Masuda S, Katsura T, et al. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics. 2006;16:119-127.
96. Fukudo M, Yano I, Yoshimura A, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics. 2008;18:413-423.
97. MacPhee IAM, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004;4:914-919.
98. Mourad M, Wallemacq P, De Meyer M, et al. The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting doseand weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. Clin Chem Lab Med. 2006;44:1192-1198.
99. Haufroid V, Wallemacq P, VanKerckhove V, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant. 2006;6:2706-2713.
100. Hesselink DA, van Schaik RH, van AM, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimustreated renal transplant recipients. Pharmacogenet Genomics. 2008;18:339-348.
101. MacPhee IA, Holt DW. A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. Transplantation. 2008;85:163-165.
102. Thervet E, Loriot MA, Barbier S, et al. Prospective randomized study of pharmacogenetic adaptation of tacrolimus treatment after renal transplantation. Transplantation. 2008;86:185.
103. Roy JN, Barama A, Poirier C, et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics. 2006;16:659-665.
104. Kuypers DR, de Jonge H, Naesens M, et al. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics. 2008;18:861-868.
105. Grinyo J, Vanrenterghem Y, Nashan B, et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int. 2008;21:879-891.
106. Barnard JB, Richardson S, Sheldon S, et al. The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection. Transplantation. 2006;82:1677-1682.
107. Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol. 2005;16:1501-1511.
108. Hebert MF, Dowling AL, Gierwatowski C, et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics. 2003;13:661-674.
109. Yamauchi A, Ieiri I, Kataoka Y, et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation. 2002;74:571-578.
110. Benkali K, Rousseau A, Picard N, et al. Impact of NR1I2 (PXR) polymorphisms on tacrolimus pharmacokinetics in renal transplant patients. Am J Transplant. 2008;8:633.
111. Stein CM, Murray JJ, Wood AJJ. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin Chem. 1999;45:1477-1484.
112. Bohler T, Nolting J, Kamar N, et al. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther Drug Monit. 2007;29:77-86.
113. Hartel C, Fricke L, Schumacher N, et al. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin Chem. 2002;48:2225-2231.
114. Hartel C, Schumacher N, Fricke L, et al. Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect. Clin Chem. 2004;50:141-151.
115. Sommerer C, Konstandin M, Dengler T, et al. Pharmacodynamic monitoring of cyclosporine A in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation. 2006;82:1280-1285.
116. Sommerer C, Giese T, Schmidt J, et al. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation. 2008;85:15-21.
117. Kowalski RJ, Zeevi A, Mannon RB, et al. Immunodiagnostics: evaluation of functional T-cell immunocompetence in whole blood independent of circulating cell numbers. J Immunotoxicol. 2007;4:225-232.
118. Stalder M, Birsan T, Holm B, et al. Quantification of immunosuppression by flow cytometry in stable renal transplant recipients. Ther Drug Monit. 2003;25:22-27.
119. Barten MJ, Tarnok A, Garbade J, et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif. 2007;40:50-63.
120. Hirano T. Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine. Int Immunopharmacol. 2007;7:3-22.
121. European Mycophenolate Mofetil Cooperative Study Group. Placebocontrolled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet. 1995;345:1321-1325.
122. Keown P, Häyry P, Mathew T. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61:1029-1037.
123. Sollinger for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 1995;60:225-232.
124. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl. 2001;7:442-450.
125. Kobashigawa J, Miller L, Renlund D, et al. A randomized activecontrolled trial of mycophenolate mofetil in heart transplant recipients. Transplantation. 1998;66:507-515.
126. Granger DK. Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials. Transplant Proc. 2001;33:3241-3244.
127. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266.
128. Hale MD, Nicholls AJ, Bullingham RES, et al. The pharmacokineticpharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683.
129. Kiberd B, Lawen J, Fraser A, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant. 2004;4:1079-1083.
130. Pawinski T, Durlik M, Szlaska I, et al. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. J Clin Pharm Ther. 2006;31:27-34.
131. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokineticpharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002;13:759-768.
132. Oellerich M, Shipkova M, Schutz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. Ther Drug Monit. 2000;22:20-26.
133. Kuypers DRJ, Claes K, Evenepoel P, et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol. 2003;43:866-880.
134. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol. 1998;9:1511-1520.
135. Shaw LM, Mick R, Nowak I, et al. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998;38:268-275.
136. van Hest RM, Mathot RAA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17:871-880.
137. Gonzalez-Roncero FM, Gentil MA, Brunet M, et al. Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. Transplant Proc. 2005;37:3749-3751.
138. Kaplan B, Meier-Kriesche HU, Friedman G, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol. 1999;39:715-720.
139. Johnson HJ, Swan SK, Heim-Duthoy KL, et al. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying d egrees of renal function. Clin Pharmacol Ther. 1998;63:512-518.
140. Naesens M, de Loor H, Vanrenterghem Y, et al. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation. 2007;84:362-373.
141. Parker G, Bullingham R, Kamm B, et al. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol. 1996;36:332-344.
142. Borrows R, Chusney G, James A, et al. Determinants of mycophenolic acid levels after renal transplantation. Ther Drug Monit. 2005;27:442-450.
143. Atcheson BA, Taylor PJ, Kirkpatrick CM, et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit. 2004;26:284-286.
144. Atcheson BA, Taylor PJ, Mudge DW, et al. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol. 2005;59:271-280.
145. Jain A, Venkataramanan R, Hamad IS, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol. 2001;41:268-276.
146. Merkel U, Lindner S, Vollandt R, et al. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients. Int J Clin Pharmacol Ther. 2005;43:379-388.
147. van Hest RM, van Gelder T, Vulto AG, et al. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2005;44:1083-1096.
148. Zicheng Y, Peijun Z, Da X, et al. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients. Br J Clin Pharmacol. 2006;62:446-452.
149. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060-1067.
150. Brunet M, Cirera I, Martorell J, et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation. 2006;81:541-546.
151. Cattaneo D, Merlini S, Zenoni S, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant. 2005;5:2937-2944.
152. Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
153. Gerbase MW, Fathi M, Spiliopoulos A, et al. Pharmacokinetics of mycophenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis. J Heart Lung Transplant. 2003;22:587-590.
154. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119-128.
155. Picard N, Premaud A, Rousseau A, et al. A comparison of the effect of ciclosporin and sirolimus on the pharmacokinetics of mycophenolate in renal transplant patients. Br J Clin Pharmacol. 2006;62:477-484.
156. Smak Gregoor PJH, de Sevaux RGL, Hene RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation. 1999;68:1603-1606.
157. Engelbertink R, Smak GP, Hesse C, et al. High mycophenolic acid area under-the-curve values in renal transplant recipients on long-term mycophenolate mofetil treatment. Transplant Proc. 2002;34:2983-2984.
158. Buchler M, Lebranchu Y, Beneton M, et al. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clin Pharmacol Ther. 2005;78:34-42.
159. Pou L, Brunet M, Cantarell C, et al. Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit. 2001;23:35-38.
160. Hohage H, Zeh M, Heck M, et al. Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function. Transplant Proc. 2005;37:1748-1750.
161. Shipkova M, Armstrong VW, Kuypers D, et al. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit. 2001;23:717-721.
162. Smak Gregoor PJ, van GT, Hesse CJ, et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant. 1999;14:706-708.
163. Schmidt LE, Rasmussen A, Norrelykke MR, et al. The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients. Liver Transpl. 2001;7:739-742.
164. Naderer OJ, Dupuis RE, Heinzen EL, et al. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol. 2005;45:219-226.
165. Borrows RM, Chusney GB, Loucaidou MM, et al. The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation. Ther Drug Monit. 2007;29:122-126.
166. Pieper AK, Buhle F, Bauer S, et al. The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant. 2004;19:2630-2633.
167. Kato R, Ooi K, Ikura-Mori M, et al. Impairment of mycophenolate mofetil absorption by calcium polycarbophil. J Clin Pharmacol. 2002;42:1275-1280.
168. Morii M, Ueno K, Ogawa A, et al. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther. 2000;68:613-616.
169. Bullingham R, Shah J, Goldblum R, et al. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol. 1996;41:513-516.
170. Naesens M, Kuypers DRJ, Streit F, et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther. 2006;80:509-521.
171. Kuypers DRJ, Naesens M, Vermeire S, et al. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther. 2005;78:351-361.
172. Naesens M, Kuypers DRJ, Verbeke K, et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation. 2006;82:1074-1084.
173. Djebli N, Picard N, Rerolle JP, et al. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics. 2007;17:321-330.
174. Kagaya H, Inoue K, Miura M, et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007;63:279-288.
175. Levesque E, Delage R, oit-Biancamano MO, et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther. 2007;81:392-400.
176. Baldelli S, Merlini S, Perico N, et al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007;8:1127-1141.
177. Inoue KP, Miura MP, Satoh SM, et al. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther Drug Monit. 2007;29:299-304.
178. Jiao Z, Ding JJ, Shen J, et al. Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. Br J Clin Pharmacol. 2008;65:893-907.
179. Miura M, Satoh S, Inoue K, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007;63:1161-1169.
180. van Agteren MM, Armstrong VWM, van Schaik RHNM, et al. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840>A gene polymorphism. Ther Drug Monit. 2008;30:439-444.
181. Miura MP, Kagaya HP, Satoh SM, et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008;30:559-564.
182. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85-118.
183. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14:2-8.
184. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation. 2005;80:S181-S190.
185. Bullingham R, Monroe S, Nicholls A, et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after singledose oral and intravenous administration. J Clin Pharmacol. 1996;36:315-324.
186. Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant. 2007;7:888-898.
187. Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation. 2006;82:1413-1418.
188. Picard N, Ratanasavanh D, Premaud A, et al. Identification of the UDPglucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005;33:139-146.
189. Schaub TP, Kartenbeck J, Konig J, et al. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol. 1999;10:1159-1169.
190. Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant. 1999;18:143-149.
191. Flechner SM, Feng J, Mastroianni B, et al. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation. 2005;79:926-934.
192. Molinaro M, Carazzone C, Barbano D, et al. Relevance of mycophenolate mofetil therapeutic drug monitoring in heart transplantation. Transplantation. 2006;82:564.
193. Pellegrini C, Ruggieri GV, Rinaldi M, et al. Mycophenolate mofetil therapeutic drug monitoring in heart transplantation: a pharmacokinetic study. Transplantation. 2006;82:555.
194. Gaston R, Kaplan B, Meier-Kriesche HU, et al. Opticept trial: efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 12 months. Am J Transplant. 2008;8:319.
195. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7:2496-2503.
196. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86:1043-1051.
197. Budde K, Arns W, Glander P, et al. Pharmacokinetic and pharmacodynamic comparison of an initially intensified dosing regimen versus a standard dosing regimen of enteric-coated mycophenolate sodium (ECMPS) in renal transplant patients: 717. Transplantation. 2008;86:251.
198. Cattaneo D, Gaspari F, Ferrari S, et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant. 2001;15:402-409.
199. Shipkova M, Wieland E, Schutz E, et al. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc. 2001;33:1080-1081.
200. Wieland E, Shipkova M, Schellhaas U, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem. 2000;33:107-113.
201. Maes BD, Dalle I, Geboes K, et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation. 2003;75:665-672.
202. Kuypers DRJ, Vanrenterghem Y, Squifflet JP, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophe-nolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit. 2003;25:609-622.
203. Heller T, van Gelder T, Budde K, et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant. 2007;7:1822-1831.
204. Premaud A, Rousseau A, Picard N, et al. Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2006;28:274-277.
205. Irtan S, Azougagh S, Monchaud C, et al. Comparison of highperformance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients. Pediatr Nephrol. 2008;23:1859-1865.
206. Salvadori M. Therapeutic equivalence of mycophenolate sodium versus mycophenolate mofetil in de novo renal transplant recipients. Transplant Proc. 2001;33:3245-3247.
207. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004;4:237-243.
208. Salvadori M, Holzer H, de MA, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004;4:231-236.
209. Ciancio G, Burke GW, Gaynor JJ, et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Transplantation. 2008;86:67-74.
210. Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant. 2005;19:199-206.
211. Hummel M, Yonan N, Ross H, et al. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Clin Transplant. 2007;21:18-23.
212. Tedesco-Silva H, Bastien MC, Choi L, et al. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant Proc. 2005;37:852-855.
213. Cattaneo D, Cortinovis M, Baldelli S, et al. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Clin J Am Soc Nephrol. 2007;2:1147-1155.
214. de Winter BC, van GT, Glander P, et al. Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet. 2008;47:827-838.
215. Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther. 2004;309:1029-1035.
216. Hesselink DA, van Hest RM, Mathot RAA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistanceassociated protein 2. Am J Transplant. 2005;5:987-994.
217. Deters M, Kirchner G, Koal T, et al. Influence of cyclosporine on the serum concentration and biliary excretion of mycophenolic acid and 7-O-mycophenolic acid glucuronide. Ther Drug Monit. 2005;27:132-138.
218. Filler G, Lepage N, Delisle B, et al. Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit. 2001;23:514-519.
219. Grinyo J, Ekberg H, Oppenheimer F, et al. Pharmacokinetics of total and free mycophenolic acid (MPA) in renal transplantation receiving standard-dose cyclosporine, low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony PK sub-study. Transplant Int. 2007;20:177.
220. Kuypers D, Ekberg H, Grinyo J, et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporine in renal transplant recipients. Clin Pharmacokinet. 2009. In press.
221. Patel CGP, Harmon MB, Gohh RYM, et al. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus. Ther Drug Monit. 2007;29:87-95.
222. Schuetz EG, Hazelton GA, Hall J, et al. Induction of digitoxigenin monodigitoxoside UDP-glucuronosyltransferase activity by glucocorticoids and other inducers of cytochrome P-450p in primary monolayer cultures of adult rat hepatocytes and in human liver. J Biol Chem. 1986;261:8270-8275.
223. Weber LT, Lamersdorf T, Shipkova M, et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. Ther Drug Monit. 1999;21:498.
224. Miura MP, Satoh SM, Inoue KP, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit. 2008;30:46-51.
225. Rae JM, Johnson MD, Lippman ME, et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther. 2001;299:849-857.
226. Oswald S, Giessmann T, Luetjohann D, et al. Disposition and sterollowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin Pharmacol Ther. 2006;80:477-485.
227. Kuypers DRJ, Verleden G, Naesens M, et al. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin Pharmacol Ther. 2005;78:81-88.
228. Shaw LM, Korecka M, Aradhye S, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol. 2000;40:624-633.
229. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995;41:1011-1017.
230. Meijers BK, Bammens B, Verbeke K, et al. A review of albumin binding in CKD. Am J Kidney Dis. 2008;51:839-850.
231. Hanada K, Ogawa R, Son K, et al. Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes. Nephron Physiol. 2006;103:179-186.
232. Kuypers DRJ, de Jonge H, Naesens M, et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther. 2008;30:673-683.
233. Glander P, Hambach P, Braun KP, et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther. 2003;41:470-476.
234. Jagodzinski P, Lizakowski S, Smolenski RT, et al. Mycophenolate mofetil treatment following renal transplantation decreases GTP concentrations in mononuclear leucocytes. Clin Sci (Lond). 2004;107:69-74.
235. Budde K, Glander P, Bauer S, et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med. 2000;38:1213-1216.
236. Langman LJ, LeGatt DF, Halloran PF, et al. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation. 1996;62:666-672.
237. Sanquer S, Maison P, Tomkiewicz C, et al. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation. Clin Pharmacol Ther. 2008;83:328-335.
238. Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant. 2004;4:2045-2051.
239. Patel CG, Richman K, Yang D, et al. Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. Ther Drug Monit. 2007;29:735-742.
240. Wang J, Yang JW, Zeevi A, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther. 2008;83:711-717.
241. Wang J, Zeevi A, Webber S, et al. A novel variant L263F in human inosine 5′-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics. 2007;17:283-290.
242. van Gelder T, Sombogaard F, van Schaik R, et al. IMPDH activity is correlated with the 3757>C polymorphism in the IMPDH type 2 gene in MMF treated kidney transplant patients. Transplantation. 2008;86:37.
243. Bremer S, Mandla R, Vethe NT, et al. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation. 2008;85:55-61.
244. Raggi M, Stangl M, Siebert S, et al. IMPDH inhibition as a key marker in renal transplantation. Transplantation. 2008;86:334.
245. van Gelder T, Sombogaard F, Glander P, et al. IMPDH activity on day 6 after kidney transplantation is significantly related to the risk of acute rejection in MMF treated patients. Transplantation. 2008;86:250.
246. Vannozzi F, Filipponi F, Di Paolo A, et al. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc. 2004;36:2787-2790.
247. Weimert NA, Derotte M, Alloway RR, et al. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit. 2007;29:141-149.